A detailed history of Jpmorgan Chase & CO transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 21 shares of BIAF stock, worth $25. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21
Previous 18 16.67%
Holding current value
$25
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$1.32 - $2.82 $3 - $8
3 Added 16.67%
21 $0
Q2 2024

Aug 12, 2024

BUY
$1.76 - $3.0 $8 - $15
5 Added 38.46%
18 $0
Q1 2024

May 10, 2024

BUY
$1.42 - $3.0 $5 - $12
4 Added 44.44%
13 $0
Q4 2023

Feb 12, 2024

BUY
$1.18 - $1.69 $2 - $3
2 Added 28.57%
9 $0
Q3 2023

Nov 14, 2023

BUY
$0.99 - $1.9 $6 - $13
7 New
7 $0

Others Institutions Holding BIAF

About bioAffinity Technologies, Inc.


  • Ticker BIAF
  • Exchange
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 2,727,580
  • Market Cap $3.35M
  • Description
  • bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...
More about BIAF
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.